Akums Drugs and Pharmaceuticals Limited Stock Price Today (NSE: AKUMS)

Akums Drugs and Pharmaceuticals Limited

772.00+6.35 (+0.83%)
Market Closed

Fundamental Score

...

Akums Drugs and Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Akums Drugs and Pharmaceuticals Limited share price today is 772.00, up +0.83% on NSE/BSE as of 16 September 2026. Akums Drugs and Pharmaceuticals Limited (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 11.82K (Cr). The 52-week high for AKUMS share price is 796.55 and the 52-week low is 409.30. At a P/E ratio of 40.52x, AKUMS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.02% and a debt-to-equity ratio of 0.02.

Akums Drugs and Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
796.55
Low
703.00
Volume
4.7L
Change
+0.89%

Akums Drugs and Pharmaceuticals Limited share price chart: 0.89% return over the past month. 52-week high ₹796.55, 52-week low ₹409.30.

Akums Drugs and Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
759.20775.00746.40772.002.36L (Cr)
780.25792.00762.15765.653.45L (Cr)
753.00784.40740.50776.353.99L (Cr)
741.10755.10740.35749.652.89L (Cr)
737.00769.00737.00741.104.34L (Cr)
754.05757.75733.15736.601.99L (Cr)
765.75772.90751.50754.651.21L (Cr)
784.40785.00748.35765.753.39L (Cr)
764.35788.00760.50780.553.36L (Cr)
778.00794.90768.20770.257.50L (Cr)

Akums Drugs and Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
780.50796.55733.15772.00-1.09%
666.70785.00656.50776.70+16.50%
623.27714.70620.00658.35+5.63%
524.50639.84517.00620.19+18.24%
550.00567.00500.05524.50-4.64%
473.90557.00473.90547.30+15.49%
472.00515.00456.55466.10-1.25%
445.00506.00424.20488.15+9.70%
453.40458.00409.30439.55-3.05%
425.95480.50414.00453.40+6.44%
463.95481.70411.40425.95-8.19%
441.50473.45437.00460.75+4.36%

Returns & Performance

Poor

Return on Equity (ROE)

8.02%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

12.58%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

6.63%

Average operating profit margin over 5 years

Dividend Yield

0.14%

Annual dividend as % of current share price

Akums Drugs and Pharmaceuticals Limited Valuation Check

Poor

Price to Earnings (P/E)

40.52x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

75.26%

% shares held by company founders/management

Poor

FII Holding

1.38%

% shares held by foreign institutional investors

Good

DII Holding

14.36%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

57.56%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

13.93%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

9.87%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-55.67%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

15.68%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

5.06x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

952.52 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Akums Drugs and Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AKUMS across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Robust Profit Growth (57.56%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Profit Growth Track Record (15.68% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (5.06x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 2.55)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹952.52 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Below-Average Return on Equity (8.02%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Premium Valuation Risk (P/E: 40.52x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Weak Earnings Growth (-55.67% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Akums Drugs and Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Akums Drugs and Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
41.9/100
772
₹11819.71
40.5
Average
8.02%
Poor
12.58%
Average
0.0
Excellent
15.68%
Excellent
9.87%
Good
0.14%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9443
₹250239.50
85.7
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1370
₹110691.61
32.8
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1672
₹96212.63
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1146
₹95674.30
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Akums Drugs and Pharmaceuticals Limited PE Ratio History

Historical price-to-earnings ratio for AKUMS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202522.60₹453.4020.1x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Akums Drugs and Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for AKUMS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

13.93%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

57.56%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

9.87%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

15.68%

Compounded annual net profit growth over 5 years

Akums Drugs and Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AKUMS — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
706
▲ Price above SMA 50 — Short-term bullish
SMA 200
543
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
392K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Akums Drugs and Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for Akums Drugs and Pharmaceuticals Limited (AKUMS) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Akums Drugs and Pharmaceuticals Limited

Loading latest quarterly results...

About AKUMS (Akums Drugs and Pharmaceuticals Limited)

Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.

Company Details

Symbol:AKUMS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Sanjeev Jain
Co-Founder, MD & Whole Time Director
Mr. Sandeep Jain
Co Founder, MD & Director
Mr. Sumeet Sood
Chief Financial Officer

AKUMS Share Price: Frequently Asked Questions

What is the current share price of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited (AKUMS) trades at ₹772.00 on NSE and BSE. Market cap ₹11.82K (Cr). Educational data only.

What is the P/E ratio of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited has a P/E of 40.52x vs industry average 34.89x.

What is the Bull Run score for Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited has a Bull Run score of 41.9/100 based on 25+ financial parameters.

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited has a dividend yield of 0.14%. Past dividends don't guarantee future payments.

What is the ROE of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited has ROE of 8.02%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited has debt-to-equity of 0.02.

Is Akums Drugs and Pharmaceuticals Limited a good investment?

Bull Run gives Akums Drugs and Pharmaceuticals Limited a score of 41.9/100. This is not investment advice — consult a SEBI-registered advisor.